eureKING, a special purpose acquisition company in healthcare dedicated to bioproduction, has submitted an offer to acquire Skyepharma, a contract development and manufacturing company (CDMO) involved in innovation and development in drug development and delivery of oral technologies. eureKING would remain listed on the Professional Segment of Euronext Paris following the completion of the transaction.

With the support of eureKARE SA, a specialized company in creating, financing, and supporting innovative biotech companies, and its founder, eureKING is aiming to create a financially strong, ultra-specialized entity within the bio-CDMO sector.

The new entity aims to address specific needs of healthcare companies dedicated to the production and manufacturing of biopharmaceuticals for other companies in the healthcare industry.

With Skyepharma and its management team, eureKING would be taking the next step in its ambitious plan to build a major European player in the field of outsourcing biopharmaceutical manufacturing and processing, capable of meeting the logistical and manufacturing needs of biotech companies and the pharmaceutical industry while supporting the development of new innovative therapies, regardless of the size or clinical development stage of these companies and their products.

Skyepharma’s scalable and manufacturing platform would facilitate eureKING’s strategy to combine companies specializing in the production of biologics, cell, and gene therapies, and live biotherapeutics – three highly innovative, fast-growing segments.

Specifically, eureKING has a clear and identified roadmap to bolster Skyepharma’s new Skyehub facility with bolt-on acquisitions, such as potentially additional state-of-the-art facilities or a European CDMO focused on cell and gene therapy. 

Alexandre Mouradian, co-founder of eureKING and founder of eureKARE SA, said: “At eureKARE, we have been focused on supporting innovative companies that can bring cutting-edge technologies to transform industries, such as healthcare. When we launched eureKING, our goal was to identify disruptive and scalable companies to help us build a leading player in Europe’s bioproduction field that can catapult the development of manufacturing processes for these innovative technologies. With Skyepharma we have found an ideal partner. By leveraging our combined experience and knowledge, we would be ideally positioned to capture vast opportunities in a growing strategic sector.”

David Lescuyer, Skyepharma’s President, and CEO said: “At Skyepharma, our purpose is to solve healthcare industry complexity. With this transaction, we would be accelerating our mission and positioning Skyepharma to have a larger role in the growing and yet fragmented biologic CDMO market, enabling us to help more clients offer the best treatments for the benefit of the patient. The collective strength of Skyepharma and eureKING’s wide networks and in-depth experience would strongly support the integration and growth of cutting-edge clinical and industrial bioproduction in France and in Europe. We are eager to collaborate with the eureKING team as we move forward.”